Cannabix Technologies Improves Performance of FAIMS Marijuana Breathalyzer – CNN Coverage
January 07 2020 - 8:45AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of marijuana breathalyzer devices
for law enforcement and the workplace, reports that engineers have
developed and deployed new ion optics methods that have resulted in
a 6 times increase in analyte signal which has increased
the sensitivity in the Company’s FAIMS (field asymmetric
waveform ion mobility spectrometry) ∆9-tetrahydrocannabinol (“THC”)
detection device. The Company has been working for the last several
months on improving “ion optics” which is a critical component of
the FAIMS system in order to better focus and maximize ion flow
through the FAIMS cell “keyhole”. Members of Cannabix
advisory team, including Dr. Yost and Dr. Purves were instrumental
in providing guidance on the latest technological enhancements
leading to this improvement. Furthermore, the Company reports that
Cannabix scientists have been testing with a single stage, direct
breath with the FAIMS device, that allows for real-time collection
and analysis of low volatility compounds without
sample preparation.
In addition, Company engineers have been pushing
forward development of its THC Breath Analyzer (“THCBA”) which
incorporates microfluidic sensor technology for the detection of
∆9-tetrahydrocannabinol (“THC”) from breath. As announced in
November, engineers have reduced the size of several components
inside the THCBA for a more compact device, over the course of
December, engineers have been further optimizing breath sample
chamber design and tested additional sensors that work in
conjunction with microfluidic sensor. Furthermore, the form factor
(exterior) design of the THCBA will see additional refinements in
due course.
The Company reports that it has received notable
media coverage from CNN in an article titled, “Testing drivers for
cannabis is hard. Here’s why” published recently in CNN Business.
The article makes mention of Cannabix Technologies’ development
work with its marijuana breathalyzer technologies. The full article
can be viewed at:
https://www.cnn.com/2020/01/02/business/cannabis-breathalyzers-are-coming-to-market/index.html
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana
breathalyzer development for law enforcement and the workplace.
Cannabix has established breath testing technologies in the pursuit
of bringing durable, portable tools to market to enhance detection
of marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking
Statements This press release contains forward-looking information
that involves various risks and uncertainties regarding future
events. Such forward-looking information can include without
limitation statements based on current expectations involving a
number of risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024